Key PointsThe rotation into defensive names is here, and the healthcare stocks seem to be accumulating the bulk of employment and business activity.Pfizer offers above-average growth at a massive discount to competitors within that sector, like Eli Lilly and AstraZeneca.Analysts see the writing on the wall and aren't afraid to tell you about their price targets.5 stocks we like better than PfizerThe defensive names, characterized by their immunity to the business cycle, in the market could soon see an inflo ...

Pfizer (PFE) has reached a major transition point. The big pharma company took center stage earlier in the COVID-19 pandemic when it became the first to launch a coronavirus vaccine. That product, Comirnaty, and the treatment Paxlovid, released later, helped Pfizer's revenue reach a record level of $100 billion in 2022; the two products made up more than half of that.Now, though, with coronavirus product demand falling and losses of exclusivity ahead for some of Pfizer's other drugs, the company's revenue i ...

Analyst Estimates for Q4 2023Q3 2023Q4 2022Revenue$14.3 billion$13.2 billion$24.3 billionAdjusted Earnings (or Loss) Per Share(19 cents)(17 cents)$1.14Adjusted Net Income (or Loss)($1.1 billion)($968 million)$6.55 billion Key Metric After Pfizer has struggled amid poor demand for its COVID-19 products, including its Paxlovid treatment and the Comirnaty vaccine, investors will want to watch for the company’s reported revenue from this segment. Analysts are projecting sales of the vaccine to fall 52% in th ...

– Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival – – If approved, PADCEV with KEYTRUDA would be the first combination in the EU to offer an alternative to platinum-containing chemotherapy, the current standard of care in first-line locally advanced or metastatic urothelial cancer – TOKYO and NEW YORK, Jan. 26, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer In ...

NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, “Astellas”) today announced that on January 26 the European Medicines Agency (EMA) validated for review a Type II variation application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) as a combination therapy for the first-line treatment of adult patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC). If approved, PADCEV with K ...

Wall Street analysts expect Pfizer (PFE) to post quarterly loss of $0.19 per share in its upcoming report, which indicates a year-over-year decline of 116.7%. Revenues are expected to be $14.36 billion, down 40.9% from the year-ago quarter.Over the last 30 days, there has been a downward revision of 1.9% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.Ahe ...

System1 Group (AIM:SYS1) climbed 23% on Wednesday as the marketing firm said recent deals with the likes of Tesco, Pfizer and M&S meant full-year expectations would be smashed. Some 60 new clients signed with AIM-listed System1 over the third quarter, taking the number to over 200 for the year so far, the company updated on Wednesday. This included the likes of Pfizer, M&S, Tesco, easyJet, Toyota, Muller, B&Q, and Just Eat most recently, with System1 providing tests to assess effectiveness of marketing idea ...

Pfizer (PFE) will report fourth-quarter and full-year 2023 results on Jan 30, before market open. In the last reported quarter, the company beat earnings expectations by 46.88%.Factors to NotePfizer’s revenues are expected to have declined in the fourth quarter of 2023 due to steep declines in revenues from its COVID-19 products on lower demand.Pfizer records direct sales and alliance revenues from its partner, BioNTech, for the COVID-19 vaccine, Comirnaty, and product revenues from its oral antiviral pill ...

I can sum up Pfizer's (PFE 0.42%) stock performance over the last couple of years in one word (and only three letters): ugh. Shares of the big drugmaker have plunged more than 50% since the high set in late 2022.Pfizer's revenue and earnings are sinking like a brick. Big hurdles for the company lie ahead. All in all, this big pharma stock might look like one that investors won't want to touch with a 10-foot pole.However, I'm actually bullish about Pfizer over the long term. Here's why it's a much better sto ...

The market expects Pfizer (PFE) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on January 30, 2024, might help the stock move higher if these key numbers are bett ...